Breaking News

Charles River, AstraZeneca Extend Strategic Partnership

Charles River remains sole provider of safety assessment and development DMPK

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories and AstraZeneca have extended their initial three-year partnership for an additional five-year period through 2020. Charles River retains its position as AZ’s preferred strategic partner for outsourced regulated safety assessment and development DMPK (drug metabolism and pharmacokinetics).   James C. Foster, chairman, president and chief executive officer of Charles River said, “We are extremely pleased that AstraZeneca has chosen to extend its relationship with Char...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters